PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3691397
- Registration Number
- NCT05838664
- Locations
- 🇫🇷
Pfizer Investigational Site, Paris, France
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5279
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
- Conditions
- Pneumococcal Disease
- Interventions
- Other: Low dose multivalent pneumococcal conjugate vaccine formulation AOther: Low dose multivalent pneumococcal conjugate vaccine formulation BBiological: Low dose of multivalent pneumococcal conjugate vaccine controlBiological: Standard dose multivalent pneumococcal conjugate vaccine control
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05831124
- Locations
- 🇺🇸
Centennial Medical Group, Elkridge, Maryland, United States
🇺🇸Rochester Clinical Research, LLC, Rochester, New York, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05822440
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Atrial Fibrillation Data Linkage Non-Interventional Study
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19388
- Registration Number
- NCT05810727
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 775
- Registration Number
- NCT05810038
- Locations
- 🇨🇳
The Second People's hospital of Hefei, Hefei, Anhui, China
🇨🇳The fourth people's hospital of chongqing, Chongqing, Chongqing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT05807490
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- Biological: C. difficile vaccine formulation 1.Biological: C. difficile vaccine formulation 2.Biological: C. difficile vaccine formulation 3.Biological: C. difficile vaccine (previously studied formulation).Other: Saline Placebo.
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 689
- Registration Number
- NCT05805826
- Locations
- 🇺🇸
HOPE Research Institute, Phoenix, Arizona, United States
🇺🇸Hope Research Institute, Phoenix, Arizona, United States
🇺🇸The Pain Center of Arizona, Phoenix, Arizona, United States
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT05799495
- Locations
- 🇺🇸
Remington-Davis, Inc, Columbus, Ohio, United States
🇺🇸Proactive Clinical Research LLC, Edinburg, Texas, United States
🇺🇸Franco Felizarta, Md, Bakersfield, California, United States
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
- Conditions
- Crohn DiseaseArthritis, RheumatoidColitis, UlcerativePsoriasis
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT05796245
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan